Clinical trials
Advanced Liver Cancer clinical trials
Below are recruiting advanced liver cancer clinical trials, each written for real people, not researchers. We’re tracking 879 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05019690RecruitingPhase 1/Phase 2
Test drug combo for advanced triple-negative breast cancer
This trial studies how well apatinib plus albumin-bound paclitaxel works for advanced triple-negative breast cancer that has come back or spread. It may help shrink tumors and control the disease by targeting cancer growth in more than one way.
Fuzhou, FujianAges 18–75 - NCT06908668RecruitingPhase 2
Adebrelimab plus chemo with or without radiation before breast cancer surgery
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
BeijingAges 18–70 - NCT07173868Recruiting
PET scans for advanced breast cancer treatment planning
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
Seoul, Gannam-guAges 19 years+ - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT06856200Recruiting
Sirolimus plus palbociclib and fulvestrant for advanced breast cancer
This trial tests a new combination of three drugs (sirolimus, palbociclib, and fulvestrant) for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The goal is to see if adding sirolimus can help control the cancer when standard hormone therapy is no longer working.
ShanghaiAges 18 years+ - NCT04827810RecruitingPhase 1
IV gamitrinib study for advanced cancers needing new options
This early-phase trial tests how safe IV gamitrinib is and how the body processes it in people with advanced cancers that can’t be controlled by standard treatment. It may also help researchers learn the best dose and whether it has signs of anti-cancer activity.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New Haven, ConnecticutAges 18 years+ - NCT06642857Recruiting
Predicting treatment response for advanced stomach cancer
This trial uses advanced testing to predict how well stomach cancer responds to chemotherapy combined with immunotherapy. It may help find the best treatment for advanced or metastatic stomach or gastroesophageal junction cancer that hasn't been treated yet.
Hangzhou, ZhejiangAges 18–75 - NCT06867822RecruitingPhase 1
Testing ProAgio for Advanced Colorectal Cancer
This trial tests a new drug called ProAgio for people with advanced or metastatic colorectal cancer. It aims to see if ProAgio can help shrink or slow the cancer when combined with standard treatments.
Birmingham, AlabamaAges 19 years+ - NCT06861088RecruitingPhase 3
Kinisoquin for preventing blood clots in pancreatic cancer
This trial tests whether an investigational drug called Kinisoquin™ can help prevent blood clots in people with advanced pancreatic cancer who are starting their first chemotherapy. It may be a good option if you are looking for extra protection against clots during treatment.
Ventura, CaliforniaAges 18 years+ - NCT06454383RecruitingPhase 1
Gemcitabine and leflunomide for advanced pancreatic cancer
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
Duarte, CaliforniaAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05267912Recruiting
Using tumor organoids to guide treatment for advanced cancers
This study tests whether growing a patient's tumor cells in a dish (called an organoid) can help doctors choose the best next treatment. It is for people with advanced colorectal or pancreatic cancer who have run out of standard options.
Bordeaux, FranceAges 18 years+ - NCT06447623RecruitingPhase 3
Apatinib plus CDK4/6 inhibitor for first-line HR+/HER2- SNF4 breast cancer
This trial tests a combination of two drugs, apatinib and a CDK4/6 inhibitor, as the first treatment for a specific type of advanced breast cancer that is HR+ and HER2-. It's designed for people with the 'SNF4' subtype, which is identified by a special analysis of your tumor sample.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04892693RecruitingPhase 2
Talazoparib for advanced breast cancer with DNA repair defects
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
SeoulAges 19 years+ - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06595563RecruitingPhase 2
PET imaging to guide HER2 breast cancer treatment sequencing
This study tests whether a special PET scan using a radioactive tracer can help doctors choose the right sequence of antibody-drug conjugates for HER2-positive advanced breast cancer. It is for patients whose cancer has already progressed on the drug T-DXd (Enhertu).
Anderlecht, Brussels CapitalAges 18 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT07068542Recruiting
New drug combo for advanced thyroid cancer
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+
Hear when a new Advanced Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced liver cancer?
- Yes. Clin2 currently lists 879 recruiting advanced liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.